year warrant to purchase up to 3,400,000 common shares of the
Company, exercisable at US$0.01 per share, issued to Abiomed in
connection with the secured promissory note.
The election of directors, the appointment of the auditors and the conversion of the note and exercise of the warrant issued to Abiomed were carried by a majority of the votes at the meeting in person or by proxy. A copy of the Voting Results, which includes the percentage outcome of the votes cast, is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
About World Heart Corporation
WorldHeart is a developer of mechanical circulatory support systems. The Company is headquartered in Oakland, California, USA with additional facilities in Salt Lake City, Utah and Herkenbosch, Netherlands. WorldHeart's registered office is Ottawa, Ontario, Canada.
Any forward-looking statements in this release are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995 and include any statements regarding the Company's ability to regain
compliance with the NASDAQ Capital Market listing requirements, as well as
other statements that can be identified by the use of forward-looking
language, such as "believes," "feels," "expects," "may," "will," "should,"
"seeks," "plans," "anticipates," or "intends" or the negative of those
terms, or by discussions of strategy or intentions. Investors are cautioned
that all forward-looking statements involve risk and uncertainties,
including without limitation: the Company's immediate need for additional
capital, risks in product development and market acceptance of and demand
for the Company's products; delisting from the NASDAQ Stock Market if
compliance with the listing standards, including the Minimum Bid Price Rule
and other minimum standards, is not regained; and other risks detailed in
the Corporation's filings with the U.S. Securities and
|SOURCE World Heart Corporation|
Copyright©2008 PR Newswire.
All rights reserved